**In silico** pharmacokinetic and molecular docking studies of small molecules derived from *Indigofera aspalathoides* Vahl targeting receptor tyrosine kinases

Sathish Kumar Paramashivam¹, Kalaivani Elayaperumal¹, Boopala bhagavan Natarajan¹, Manjula devi Ramamoorthy¹, Suganthana Balasubramanian² & Kannan Narayanan Dhiraviam¹*

¹Department of Plant Biotechnology, School of Biotechnology, Madurai Kamaraj University, Madurai-625021, Tamil Nadu, India; ²Department of Chemistry, Fatima College, Maryland, Madurai-625018; Kannan Narayanan Dhiraviam – Email: kannan.biotech@mkuniversity.org; Phone: +91-9965428166;*Corresponding author

Received January 07, 2015; Accepted January 28, 2015; Published February 28, 2015

**Abstract:** Angiogenesis is the formation of new blood vessels from preexisting vascular network that plays an important role in the tumor growth, invasion and metastasis. Anti-angiogenesis targeting tyrosine kinases such as vascular endothelial growth factor receptor 2 (VEGFR2) and platelet derived growth factor receptor β (PDGFRβ) constitutes a successful target for the treatment of cancer. In this work, molecular docking studies of three bioflavanoid such as indigocarpan, mucronulatol, indigocarpan diacetate and two diterpenes namely erythroxydiol X and Y derived from *Indigofera aspalathoides* as PDGFRβ and VEGFR2 inhibitors were performed using computational tools. The crystal structures of two target proteins were retrieved from PDB website. Among the five compounds investigated, indigocarpan exhibited potent binding energy ΔG = -7.04 kcal/mol with VEGFR2 and ΔG = -4.82 with PDGFRβ compared to commercially available anti-angiogenic drug sorafenib (positive control). Our results strongly suggested that indigocarpan is a potent angiogenesis inhibitor as ascertained by its potential interaction with VEGFR2 and PDGFRβ. This hypothesis provides a better insight to control metastasis by blocking angiogenesis.

**Keywords:** VEGFR2, PDGFRβ, Angiogenesis, Lipinski rules, Autodock, Indigocarpan

**Background:** Receptor tyrosine kinases (RTKs) constitutes a large family of growth factors all of which contain an integral protein tyrosine kinase (PTK). Growth factors like PDGF, VEGF, EGF, FGF and IGF-1 belong to RTKs are involved in regulating cellular growth and development [1]. Angiogenesis is the sprouting of new blood vessels from existing vasculature, is a crucial process in tumor growth and metastasis. This process is critical in normal physiological development but excessive angiogenesis is a common cause in a wide range of pathologies, most notably cancer [2]. During tumor growth, transformed cells secrete a group of pro-angiogenic proteins such as vascular endothelial growth factors (VEGFs), fibroblast growth factors (FGFs) and platelet derived growth factors (PDGFs) [3]. Among the many proangiogenic factors, VEGF and PDGF have been identified as the most important regulator of tumor angiogenesis [4]. These proteins stimulate endothelial cell proliferation, migration and vascular remodeling, which contribute to tumor neovascularization. An enriched blood supply provides the tumor with nutrients for further growth and facilitates invasion and metastasis [5].

Retardation of angiogenesis process by interfering these signaling cascades have been emerged as one of the most...
potential new approaches for the treatment of cancers [6]. Out of the three VEGF receptors, vascular endothelial growth factor receptor 2 (VEGFR2) is reported to be the most important regulator of cancer angiogenesis, mediating the majority of angiogenic effects of VEGF-A [7]. VEGF receptor activation depends on PDGF upon activation of PDGF receptor, VEGF-A binding to VEGFR2 promotes receptor dimerization, tyrosine kinase activation and trans-autophosphorylation of specific tyrosine residues within the cytoplasmic domain [8]. Platelet-derived growth factors (PDGFs) represent a group of growth factors consists of five different disulphide-linked dimers, PDGF-AA, -BB, -AB, -CC and -DD that act through the two receptors PDGFRα and PDGFRβ [9]. After receptor activation, several intracellular pathways are stimulated; leading to cell proliferation and several other crucial processes that play a significant role in angiogenesis [10]. Blocking of PDGF receptor beta and VEGFR2 retards angiogenesis, vascular maturation and cell proliferation leading to tumor regression. Bevacizumab (Avastin), Sunitinib malate and Sorafenib, are inhibitors of VEGFR2 and PDGFRβ approved by FDA [11].

The medicinal plant Indigofera aspalathoides (Family- Fabaceae) found in South India and Srilanka and is traditionally used for treating various skin disorders and tumors. Phytochemical and Pharmacological studies have been investigated much due to its anti-cancerous and antioxidant property [12]. The major bioactive compounds are indigocarpan, indigocarpan diacetate, mucronulatol, erythroxydiol X and erythroxydiol Y [13]. Thus, plant derived natural bioactive compounds can be a better way to find a new potential anti-PDGF and VEGF agents with less side effects to control metastasis by angiogenesis through interfering tyrosine kinases. Many reports are available on phytochemistry, and pharmacological action of I. aspalathoides, the main bioactive compounds and their mechanism of action to control the angiogenesis not been reported. In this perspective, in the present work I. aspalathoides’ key metabolites indigocarpan, indigocarpan diacetate, mucronulatol, erythroxydiol X and erythroxydiol Y were studied for their inhibitory activity on PDGF and VEGF receptor tyrosine phosphorylation. Different cheminformatics approaches like target identification, active site prediction, drug likeness properties, ADMET properties, drug metabolism, biological activity, molecular docking of selected phytoligands with VEGFR2 and PDGFRβ were studied.

Figure 1: Structure of various phytoligands reported in I. aspalathoides

Figure 2: The three dimensional structure of selected target proteins a) VEGFR2 – 3VHE; b) PDGFRβ (Only X Chain – 3MJG)

Methodology:

**Hardware and Software used**

All the computational studies were executed by the PC windows 7 ultimate with Intel Core i5 microprocessor, 4 GB memory and 32 Bit operating system. We used biological databases such as PubChem, PDB (Protein Data Bank) and PharmMapper server. Online tools such as Molinspiration, Osiris property explorer, admetSAR, Online pass server and Meta print 2D and software’s like Autodock 4.2, Chemdraw Ultra 6.0 were used.

**Potential therapeutic target identification**

The precise identification of drug target was performed by PharmMapper server (http://59.78.96.61/pharmmapper). It is a freely accessed web server designed to identify potential target candidates for the given plant derived small molecules by means of reverse pharmacophore mapping approach. This model is supported by a large repertoire of pharmacophore database composed of more than 7000 receptor based pharmacophore models that are extracted from Target Bank, BindingDB, Drug Bank and Potential Drug Target Database. A strategy algorithm of sequential combination of triangle hashing and genetic algorithm was designed to solve the molecule pharmacophore best fitting task. The possibility of potential interaction between compounds derived from I. aspalathoides and protein tyrosine kinase receptors (PDGFRβ & VEGFR2) were studied using this server. The SDF format was submitted to the pharmMapper server to find out fit score. The target set was limited to human targets, and all parameters were kept as default [14].

**Active Site prediction**

The active sites of selected target proteins were identified by using CASTp server (Computed Atlas of Surface Topography of proteins) (http://cast.engr.uiuc.edu). It detects all the feasible pockets in the protein structure. It measures analytically the area and volume of each pocket and cavity, both in solvent accessible surface (SA, Richards’ surface) and molecular surface (MS, Connolly’s surface) [15]. The first pocket was chosen as the biologically most favorable active site for docking studies.

**Preparation of phyto-ligand**

The 3D structure of the ligand molecule Mucronulatol was retrieved from Pubchem (http://pubchem.ncbi.nlm.nih.gov /pccompound) in SDF format, and converted to PDB format using Accryl Discovery studio visualizer 3.5 software. Other
Ligands were drawn by using Chemdraw ultra 6.0 and are shown in (Figure 1).

Figure 3: Binding pocket identification by CASTp server. (a,c) Shows the binding sites of PDGFRβ and VEGFR2 protein respectively, and (b,d) Green color boxes highlights the amino acid residues present in the binding site.

Preparation of target protein
Two targets VEGFR2 (PDB ID: 3VHE) and PDGFRβ (PDB ID: 3MJG) retrieved from PDB website were viewed by discovery studio visualizer 3.5 (Figure 2) and used for docking simulation. The crystal structures of target proteins were retrieved from RCSB protein data bank (http://www.rcsb.org/pdb/home/home.do). The VEGFR2 protein was resolved by X-ray diffraction method with a resolution factor of 1.55 Å, R value 0.186 and other target protein PDGFRβ was resolved by X-Ray diffraction method with a resolution factor 2.30 Å, R value 0.237. After obtaining the pdb format of proteins, they were processed by removing native ligand and crystalline water from the structure and subjected for docking studies.

In silico pharmacokinetics analysis
a) Molinspiration
Molecular descriptors and drug likeliness properties of compounds were analyzed using the tool Molinspiration server (http://www.molinspiration.com), based on Lipinski Rules of five [16]. The rule states that most “druglike” molecules must have log P ≤ 5, molecular weight ≤ 500, number of hydrogen bond acceptors ≤ 10, and number of hydrogen bond donors ≤ 5. Molecules violating more than one of these rules may have problems with oral bioavailability. Molinspiration supports for calculation of important molecular properties such as (LogP, polar surface area, number of hydrogen bond donors and acceptors), as well as prediction of bioactivity score for the most important drug targets (GPCR ligands, kinase inhibitors, ion channel modulators, enzymes and nuclear receptors [17]. TPSA was used to calculate the percentage of absorption (%ABS) using the equation reported by [18]. Percentage of absorbance = 109 − 0.345 × TPSA.

b) admetSAR Predictions
The pharmacokinetic properties such as Absorption, Distribution, Metabolism, Excretion and the Toxicity of the compounds can be predicted using admetSAR (http://www.admetexp.org) database. In admetSAR, web based query tools incorporating a molecular build-in interface enable the database to be queried by SMILES and structural similarity search. It provides the latest and most comprehensive manually curated data for diverse chemicals associated with known ADMET profiles (admetSAR@LMMD) [19].

c) Toxicity risk assessment
To identify the any undesirable toxic properties of our compounds, Osiris Property Explorer (http://www.organic-chemistry.org/prog/peo/) was used. The prediction was based on the functional group similarity for the query molecules with the in vitro and in vivo validated compounds present in this database. The toxic properties such as mutagenic, tumorogenic, irritant, reproductive effects, drug- relevant properties [c Log P, Log S (Solubility)], molecular weight, and overall drug-score were calculated. The results were visualized using different
color codes. Green color shows less toxic, orange color shows high tendency of toxicity.

**Metabolic site prediction by MetaPrint2D**

MetaPrint2D is a tool for predicting the sites of a molecule that are most likely to undergo Phase I metabolism, based on their similarity to known and unknown sites of metabolism to be metabolized [20]. It builds based on a database of atom environments found in molecules known to undergo metabolic transformation, such as the data found in the Symyx(R) (previously MDL), Metabolite database http://www.symyx.com, which contains over 80,000 metabolic transformations of xenobiotics, curated from reports in scientific literature. This software was used on the web platform (http://www-metaprint2d.ch.cam.ac.uk /metaprint2d/), by uploading the SMILES string of compounds.

**Molecular docking Simulation**

To validate drug- target association, the molecular docking stimulation was performed on active compounds with PDGFRβ & VEGFR2 by Autodock software (version 4.2) by employing Lamarckian genetic algorithm [21]. The receptor was kept rigid, while ligands were set flexible to rotate and explore most probable binding poses. All the torsional bonds of ligands were set free by Ligand module in AutoDock Tool (ADT). The Grid was set at the centre of active site pocket, which covers all the residues present inside the active site pocket with 60×60×60 points in x, y, z direction and 14.631, -9.472, -24.167 grid centre for VEGFR2. Similarly another active site pocket with 65×65×65 points in x, y, z direction and 1.583, -2.444, -5.305 grid centre was set for PDGFRβ. The parameters were saved as grid parameter file (.gpf) and followed by Autogrid run. In third step of docking, parameter files (.dpf) were prepared in which genetic algorithm was selected, the value of which remains as default. These values determine the optimal run parameter which depends upon the nature of ligand molecules and proteins (receptor). Fifty generations were set for each GA run and each run with a population size of 150. A maximum mutation rate is 0.02 and crossing over rates of 0.08 were used to generate docking trails for subsequent generation. This was followed by saving the parameters as docking parameter file (.dpf) and finally subjected to autodock run. The results generated were visualized in Discovery studio visualizer 3.5. The interactions were studied in terms of minimum binding energy (Kcal/mol), Ki (Inhibition constant) value (μM), and number of hydrogen bonds and stacking interaction formed between the active site residues of macromolecule and ligand.

**Biological activity spectrum (BAS)**

BAS of a compound represents the complex of pharmacological effects, physiological and biochemical mechanisms of action, specific toxicity (mutagenicity, carcinogenicity, teratogenicity, and embryotoxicity) which can be revealed in compound’s interaction with biological system. BAS describes the intrinsic properties of the compound depended on its structural particularities [22]. The set of pharmacological effects, mechanisms of action, and specific toxicities that might be exhibited by a particular compound in its interaction with biological entities are predicted by PASS and it is termed as “biological activity spectrum” of the compound [23]. PASS uses Sdffile (.sd) or MOLfile (.mol) formats as an external source of structure and activity data (http://www.mdl.com). Their values vary from 0.000 to 1.000. Only those activity types for which \( P_a > P_t \) were considered possible.
protein was characterized to obtain residues around the probe radius 1.4Å. The green color represents amino acid residues involved in configuration of binding pockets which is ranging from GLU63-ASN298.

**Molinspiration Calculation**

The CLogP (octanol / water partition co efficient) was calculated by the methodology developed by Molinspiration as a sum of fragment based contributions and correlation factors. The molecular descriptors of five compounds given in Table 2 (see supplementary material) were tested to Lipinski’s rule of five, interesting all the ligands which we selected have molecular weight in the range of 292 – 400 (< 500). Low molecular weight drug molecules (<500) are easily transported, diffuse and absorbed as compared to heavy molecules. Molecular weight is an important aspect in therapeutic drug action; If it increases beyond certain limit, the bulkiness of the compounds also increases correspondingly, which in turn affects the drug action [25]. Number of hydrogen bond acceptors (O and N atoms) and number of hydrogen bond donors (NH and OH) in the tested compounds were found to be within Lipinski’s limit range from 7-2 & 3-2 i.e. less than 10 and 5 respectively.

Lipophilicity (log P value) and TPSA values are two important properties for the prediction of per oral bioavailability of drug molecules [26]. Permeability property of compounds were analyzed, the calculated log P value of five compounds was ranging from 3.381 to 4.759 (<5), which is the acceptable limit for the drugs to be able to penetrate through biomembranes. Topological Polar Surface Area (TPSA) was calculated as described by [17]. O- and N- centered polar fragments were considered. TPSA has shown to be a very good descriptor characterizing drug absorption, including intestinal absorption, bioavailability, Caco-2 permeability and BBB penetration.

The highest degree of lipophilicity was found with all the compounds which are an indication for good lipid solubility that will help the drug to interact with the membranes. TPSA was calculated from the surface areas that are occupied by oxygen and nitrogen atoms and by hydrogen atoms attached to them. Thus, the TPSA is closely related to the hydrogen bonding potential of a compound [27]. In our study, all ligands exhibited 77% to 95% absorption, indicates good bioavailability by oral route. Good bioavailability is more likely for compounds with ≤10 rotatable bonds and TPSA of ≤ 140 Å [28]. As the number of rotatable bonds increases, the molecule becomes more flexible and more adaptable for efficient interaction with a particular binding pocket. Interestingly, all the five compounds have 3-6 rotatable bonds and flexible.

Drug likeliness property of five compounds against GPCR ligand, ion channel modulator, kinase inhibitor, nuclear receptor ligand, protease inhibitor and enzyme inhibitory activity were studied and summarized in Table 3 (see supplementary material). The molecule having bioactivity score more than 0.00 is likely to possess considerable biological activities, values -0.50 to 0.00 are expected to be moderately active and if score is less than -0.50, it is presumed to be inactive [29]. The results of the present study demonstrated that the investigated compounds were biologically active and produced the physiological actions by interacting with GPCR ligands, nuclear receptor ligands, inhibit protease and other enzymes. GPCR ligand-based signaling cascade was used for the development of a new functional drug with increased binding selectivity profile and less undesirable effects. Though bioactivity score for GPCR ligand was found to be >0.00 for all tested compounds, but the highest score 0.24 was observed for indigocarpan closely followed by the compound Erythroxylol X (0.22). Ion channel modulators allowed the movement of charged particles across cell membranes and are important therapeutic targets which are modulated by a range of therapeutic drugs. Bioactivity score for ion channel modulator activity was in between 0.00 and -0.50. Similar results were obtained for all five compounds showed score value of >-0.50. Kinase inhibitors for development of selective inhibitors that can block or modulate diseased signaling pathways are considered a promising approach for drug development [30]. Bioactivity scores for nuclear receptor ligand, protease inhibitor and enzyme inhibition was found to be in the range of 0.38 - 0.68, 0.02 - 0.35 and 0.51- 0.51 respectively.

**admetSAR prediction**

The ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) properties of the target compounds were calculated using admetSAR as described by [31]. Blood-Brain Barrier (BBB) penetration, HIA (Human Intestinal Absorption), Caco-2 cell permeability and AMES test were calculated. The predicted ADMET data were summarized in Table 4 (see supplementary material). The cytochrome P450 super family plays an important role in drug metabolism and clearance in the liver, and the most important isoforms are CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4 [32]. Thus, inhibition of cytochrome P450 isoforms might cause drug-drug interactions in which co-administered drugs fail to metabolized and accumulate to toxic levels [33]. The analysis showed ROS to be a substrate for P-glycoprotein, which effuxes drugs and various compounds to undergo further metabolism and clearance. If P-glycoprotein is induced, drugs in the medication would be transported out of the cells at a greater rate and could lead to therapeutic failure because the drug concentration would be lower than expected [34]. Therefore, dosage control and knowledge of co-administered drugs might be considered to reduce therapeutic failure. Based on the predicted values of admetSAR, all the selected phytoligands are able to penetrate to BBB, Caco-2 and absorbed by human intestines. Furthermore, all the compounds did not show any acute toxicity and mutagenic effect with respect to the AMES test data.

**Biological activity predictions**

In order to find out the possible biological activity of selected bioactive constituents were obtained by using PASS online server. The set of pharmacological effects, mechanisms of action, and specific toxicities, that might be exhibited by a particular compound in its interaction with biological entities, and which is predicted by PASS, is termed the “BAS” of this compound [24]. The Pa and Pi values vary from 0 to 1, and Pa + Pi < 1, since these probabilities are calculated independently. Pa and Pi can be considered to be measures of the compound under study belonging to the classes of active and inactive compounds respectively.
The PASS prediction results denoted that the highest Pa value than Pi value occurred for antineoplastic and thereby it obviously showed the anticancerous potential of selected compounds evaluated in Table 5 (see supplementary material). All the five compounds showed anti-neoplastic property, and the values ranges from 0.342-0.67. However, among the five mucronulatol showed a strong Pa value while compared to erythroxydiol X &Y. These compounds may block metastasis by blocking angiogenesis by interfering VEGFR2 and PDGFRβ as evidenced by docking studies.

**Toxicity prediction by Osiris**

Structure based design is now fairly routine but many potential drugs fail to reach the clinic because of ADME/Tox liabilities. One important class of enzymes, responsible for many ADMET problems, is the cytochromes P450. Inhibition of these or production of unwanted metabolites can result in many adverse drug reactions. Toxicity risks (mutagenicity, tumorigenicity, irritation, reproduction) and physico-chemical properties (cLogP, solubility, drug-likeness and drug-score) of selected compounds were calculated by Osiris and their results were shown in Table 6 (see supplementary material). In the present study, drug-likeness property and toxicity were studied using Osiris tools and indicated no Toxicity risks (mutagenicity, tumorogenicity, irritation, reproduction) and revealed a good score as compared to positive control Sorafenib.

Drug solubility is an important factor that affects the movement of a drug from the site of administration into the blood. It is known that insufficient solubility of drug can leads to poor absorption [35]. All the compounds shown good soluble while compared to sorafenib. The Drug-Score values were in the range of 0.08 to 0.85. The drug likeliness is another important parameter in drug development. Because drug like molecules exhibit favorable absorption, distribution, metabolism, excretion, toxicological (ADMET) parameters. Currently, there are many approaches to assess a compound drug-likeness based on topological descriptors, fingerprints of molecular drug-likeness structure keys, cLogP and molecular weight [36]. Toxicity risk includes mutagenic, tumoregenic, irritant, reproductive effective parameters and green color which represents the drug conforming property. Interestingly, all our compounds appeared as green color, which clearly indicates no toxicity (Figure 4).

Figure 5: Plot of Metaprint 2D predictions. Site of metabolism; the atoms in red color that most will be metabolized are colored according to the likelihood of a metabolic site; High: red, Medium: orange, Low: green, very low is not colored, and No data: grey. NOR indicates the Normalized Occurrence Ratio; a high NOR indicates a more frequently reported site of metabolism in the metabolite database.

**MetaPrint2D**

MetaPrint2D is a fast, efficient and accurate predictor of both the sites and products of metabolism in small molecule drugs using circular fingerprints and substrate/product ratios [37]. The atoms indicated in red color would be metabolized high followed by medium orange color, low green color, and very low is not colored. Our MetaPrint2D predicted that the various oxygen and methoxy group were most likely to be metabolized (colored in red) in the flavonoid and diterbenes, followed by the group colored in orange and then by the groups marked in green. Although all the compounds have metabolic site, indigocarpan have more metabolic site than other compounds.
Molecular Docking Simulations

The molecular interaction leading the ligand from the surface of the protein to the active site reveals the cytotoxicity of the flavonoids which have strong affinities towards the target proteins that were examined in the docking analysis. Among the five selected bioactive compounds listed in Table 7 & 8 (see supplementary material), indigocarpan, an isoflavonoid compound were found to consistently have lower binding energies and showed higher interaction with proteins VEGFR2 and PDGFRβ. Docking results showed that the bioactive compound indigocarpan has the lowest binding energy of $-7.04$ Kcal/mol, lowest ligand efficiency value of $-0.31$ Kcal/mol, lowest inhibitory constant of $6.88\mu$M with VEGFR2 protein. It showed lowest binding energy of $-4.82$ Kcal/mol, lowest ligand efficiency value of $-0.21$ Kcal/mol and lowest inhibitory constant of $293.55\mu$M were observed for PDGFRβ protein. This suggests that therapies that target a wide range of RTKs will provide a more effective and long term anti-angiogenic effects than those that target a limited numbers of growth factor receptors [39].

a) Binding affinity of phytoligands with receptor tyrosine kinases

The activation of VEGFR2 kinase is known to be an ATP-consuming process. The ATP-binding site of VEGFR2 is located between the N-terminal lobe and C-terminal lobe within the catalytic domain. Many kinase inhibitors act as ATP minetics and compete with the cellular ATP for the binding with the ATP binding site and subsequently suppressing the receptor autophosphorylation [40]. It has been previously reported that the ATP binding site of VEGFR2 is mainly constituted with residues such as LEU 868, GLU 883, LYS 885, GLU 915, PHE 916, CYS 917, LYS 918, PHE 919, GLY 920, ASN 921, LEU 926, ARG 927, SER 1035, ASP 1044 and LYS 1053 [41]. In our present study, as shown in Figure 6c it has been viewed that indigocarpan stably locate at the ATP binding pocket near the hinge region. Hydrogen bonding interaction makes the lead compound Indigocarpan (C-3 position of hydroxyl group in ring A) interacts with the (Sulfur and basic amino acid group of the residues) main chain of Cys 919 and Lys920 at a distance of $1.85\AA$ & $2.47\AA$ and it has Vander Waals interaction with residues such as Phe 918, Gly 841, Asn 923, Val 848, Phe 1047, Lys 868, Asp 1046, Cys 1045, Val 899, Val 916, Leu 1035, Leu 840, and Ala 866. These interactions mediate the binding of indigocarpan to the ATP binding site of VEGFR2 and hence inhibit the function of VEGFR2.

Similarly, PDGFRβ as shown in Figure 7b has hydrogen bonding interaction with indigocarpan (C-9th position of hydroxyl group and the corresponding phenyl ring D) could interact with the (oxygen atom) main chain of Thr88 (1.89Å), THR86 (2.00Å), THR86 and THR88 are found to be the major active residues for the inhibition of PDGFRβ. Vander Waals interaction occurs with residues Met 65, Pro 69 and Leu 90. The presence of a methoxy group at C3 & C9 position seemed to be an important structural requirement for the cytotoxic activity of the indigocarpa compound compared with other compounds. Specifically, the presence of methoxy group in the benzofuran ring which enables the ligand to fit within the ATP binding residues of PDGFRβ to inhibit its activity. From this it is evident that Indigocarpan may act as potent tyrosine kinase inhibitor than Sorafenib (positive control) in respect of its binding affinity and inhibitory activity against receptor tyrosine kinases.

Figure 6: The favorable binding portion of indigocarpan with lowest binding free energy in the ATP-binding site of VEGFR2 (PDB ID: 3VHE) as analyzed by molecular docking study. (a) 2D structure of Indigocarpan, (b) The three dimensional diagram displays
the interaction of indigocarpan (the green stick) to the ATP binding site of VEGFR2 with the labeled amino acid residues CYS 919 and LYS 920 which significantly contributed to the binding. (c) The two dimensional diagram shows the interactions of indigocarpan to the amino acid residues. (d, e) denotes the binding mode of Sorafenib with VEGFR2. Similarly, colors of the residues indicate the forms of interactions as follows: van der Waals forces, green; polarity, magenta. Green arrow represents H-bonding with the amino acid main chain.

Figure 7: The favorable binding position of indigocarpan with lowest binding free energy of PDGFRβ (PDB ID: 3MJG) as analyzed by molecular docking study. (a) The three-dimensional diagram displays the interaction of indigocarpan (green stick) with PDGFRβ labeled amino acid residues of THR86 and THR88 which significantly contributed to the binding. (b) The two dimensional diagram shows the interactions of indigocarpan to the amino acid residues in the ATP- binding site. (c & d) denotes the binding mode of Sorafenib with PDGFRβ. Similarly, colors of the residues indicate the forms of interactions as follows: van der Waals forces, green; polarity, magenta; Green arrow represents H-bonding with the amino acid main chain.

Conclusion:
Among the five compounds, indigocarpan has potent inhibitory activity against angiogenic targets namely PDGFRβ and VEGFR2. Targeting VEGFR2 and PDGFRβ, which simultaneously targets endothelial cells and pericytes, acts as a potent anti-vascular strategy including endothelial cell apoptosis and tumor blood vessel regression. Future studies will have to address the stability of protein-ligand complex by molecular dynamic simulation. However, experimental studies will also have to address the interaction of indigocarpan with targets.

Acknowledgement:
Dr. Kannan thanks Science and Engineering Research Board (SERB) for financial assistance (No. SB/YS/LS-148/2013), New Delhi, Government of India.

References:
[1] Panday A et al. J Med Chem. 2002 45: 3772 [PMID: 12166950]
[2] Hanahan D & Weinberg RA, Cell. 2011 144: 646 [PMID: 21376230]
[3] Carmeliet P & Jain RK, Nature. 2011 473: 298 [PMID: 21593862]
[4] Ferrara N et al. Biochem Biophys Res Commun. 2005 333: 328 [PMID: 15961063]
[5] Carmeliet P, Oncology. 2005 69: 4 [PMID: 16301830]
[6] Kim JH et al. Mol vis. 2009 15: 1868 [PMID: 19756180]
[7] Neufeld G et al. FASEB J. 1999 13; 9 [PMID: 9879295]
[8] Koch S et al. Biochem J. 2011 437: 169 [PMID: 21711246]
[9] Heldin CH et al. Arch Biochem Biophys. 2002 398: 284 [PMID: 11831861]
[10] Tallquist M & Kazlauskas A, Cytokine Growth Factor Rev. 2004 15: 205 [PMID: 15207812]
[11] Murukesh N et al. Br J Cancer. 2010 102: 8 [PMID: 20010945]
[12] Boopala bhagavan N et al. J Pharm Res. 2013 6: 350
[13] Selvam C et al. Tetrahedron Lett. 2004 45: 4311
[14] Liu X et al. Nucleic Acids Res. 2010 38: W609 [PMID: 20430828]
[15] Dundas J et al. Nucleic Acids Res. 2006 34: W116 [PMID: 16844972]
[16] Lipinski CA et al. Adv Drug Deliv Rev. 2001 46: 3 [PMID: 11259830]
[17] Ertl P et al. J Med Chem. 2000 43: 3714 [PMID: 11020286]
[18] Zhao YH et al. Pharm Res. 2002 19: 1446 [PMID: 12425461]
[19] Cheng F et al. J Chem Inf Model. 2012 52: 3099 [PMID: 23092397]
[20] Carlsson L et al. BMC Bioinformatics. 2010 11: 362 [PMID: 20594327]
[21] Morris GM et al. J Comput Chem. 1998 19: 1639
[22] Lagunin A et al. Bioinformation. 2000 16: 747
[23] Poroikov VV et al. J Chem Inf Comput Sci. 2003 43: 228 [PMID: 12546557]
[24] Liao X et al. Plos one. 2013 8: e82294 [PMID: 24358167]
[25] Srimai V et al. Med Chem Res. 2012 22: 5314
[26] Chang LC et al. J Med Chem. 2004 47: 6529 [PMID: 15588088]
[27] Clark DE, J Pharm Sci. 1999 88: 807 [PMID: 10430547]
[28] Veber DF et al. J Med Chem. 2002 45: 2615 [PMID: 12036371]
[29] Verma A, Asian Pac J Trop Biomed. 2012 2: S1735
[30] Chatterjee S et al. Bioinformation. 2012 8: 1195 [PMID: 22275719]
[31] Cheng F et al. J Chem Inf Model. 2012 52: 3099 [PMID: 23092397]
[32] Vasanthanathan P et al. Drug Metab Dispos. 2009 37: 658 [PMID: 19056915]
[33] Lynch T & Price A, Am Fam Physician. 2007 76: 391 [PMID: 17708140]
[34] Levin GM, Curr Psychiatr. 2012 11: 38
[35] Muegge I, Med Res Rev. 2003 23: 302 [PMID: 12647312]
[36] Tetko IV, Drug Discov Today. 2006 11: 700 [PMID: 16846797]
[37] Boyer S et al. J Chem Inf Model. 2007 47: 583 [PMID: 17302400]
[38] Fraga AGM et al. In: 30th Reunião Anual da Sociedade Brasileira de Química, Águas de Lindóia - SP, Abstracts of Papers. Sociedade Brasileira de Química, 2007 MD-053
[39] Erber R et al. FASEB J. 2004 18: 338 [PMID: 14657003]
[40] Noble ME et al. Science. 2004 303: 1800 [PMID: 15031492]
[41] Yang Y et al. Bioorg Med Chem Lett. 2010 20: 6653 [PMID: 20943391]

Edited by P Kangueane

Citation: Paramashivam et al. Bioinformation 11(2): 073-084 (2015)

License statement: This is an open-access article, which permits unrestricted use, distribution, and reproduction in any medium, for non-commercial purposes, provided the original author and source are credited
Supplementary material:

Table 1: The possibility of putative targets identification by reverse pharmacophore mapping approach

| S. No | Phytoligands       | Target     | Possibility | Fit score | Normalized fit score | 'Z' score  |
|-------|--------------------|------------|-------------|-----------|----------------------|------------|
| 1     | Mucronulatol       | VEGFR 2    | Yes         | 3.196     | 0.5327               | -0.0644209|
| 2     | Indigocarpan       | VEGFR 2    | Yes         | 3.113     | 0.3459               | -0.00512483|
| 3     | Indigocarpan diacetate | VEGFR 2    | Yes         | 3.03      | 0.3371               | -0.261993 |
| 4     | Erythroxydiol X    | VEGFR 2    | Yes         | 2.866     | 0.5732               | -0.219105 |
| 5     | Erythroxydiol Y    | VEGFR 2    | Yes         | 2.985     | 0.3731               | -0.943455 |

Table 2: Molinspiration calculation of selected compounds

| S.No | Selected bioactive compounds | Mi logp | TPSA | No.of atoms | MW | N.NH | N.OH | Vol | nrotb |
|------|------------------------------|---------|------|-------------|----|------|------|-----|-------|
| 1    | Mucronulatol                 | 2.631   | 85   | 22.0        | 302.326 | 5 | 2 | 271.153 | 3 |
| 2    | Erythroxydiol X              | 3.381   | 95   | 21.0        | 292.463 | 2 | 2 | 303.265 | 2 |
| 3    | Erythroxydiol Y              | 4.186   | 95   | 22.0        | 306.49 | 2 | 2 | 324.769 | 2 |
| 4    | Indigocarpan                 | 2.286   | 82   | 23.0        | 316.309 | 6 | 2 | 269.322 | 2 |
| 5    | Indigocarpan diacetate       | 1.86    | 78   | 29.0        | 400.383 | 0 | 0 | 342.345 | 6 |
| 6    | Sorafenib (positive control) | 4.759   | 77   | 32.0        | 464.831 | 7 | 3 | 368.258 | 6 |

Table 3: Drug likeliness of selected compounds

| S.No | Name of compounds | GPCR | ICM | KI | NRL | PI | EI |
|------|------------------|------|-----|----|-----|----|----|
| 1    | Indigocarpan     | 0.24 | -0.16 | -0.10 | -0.06 | -0.35 | 0.19 |
| 2    | Erythroxydiol X  | 0.22 | 0.26 | -0.25 | 0.60 | 0.18 | 0.48 |
| 3    | Erythroxydiol Y  | 0.20 | 0.12 | -0.28 | 0.68 | -0.02 | 0.51 |
| 4    | Mucronulatol     | 0.02 | -0.08 | 0.00 | 0.38 | -0.22 | 0.46 |
| 5    | Indigocarpan diacetate | 0.11 | -0.20 | -0.23 | -0.07 | -0.27 | 0.27 |
| 6    | Sorafenib (+ ve control) | 0.18 | 0.00 | 0.44 | -0.07 | 0.11 | 0.08 |

GPCR: G-Protein coupled receptor, ICM: Ion Channel modulator, KI: Kinase inhibitor, NRL: Nuclear receptor ligand, PI: Protease inhibitor, EI: Enzyme inhibitor.

Table 4: admetSAR prediction of compounds

| ADMET | Erythroxydiol X | Erythroxydiol Y | Indigocarpan | Indigocarpan diacetate | Mucronulatol |
|-------|-----------------|-----------------|--------------|------------------------|--------------|
| Absorption | BBB             | BBB             | BBB          | BBB                    | BBB          |
| HIA    | HIA             | HIA             | HIA          | HIA                    | HIA          |
| Caco-2 | Caco2           | Caco2           | Caco2        | Caco2                  | Caco2        |
| P-gp substrate | Substrate | Substrate | Substrate | Non-Substrate | Substrate |
| P-gp inhibitor | Non-Inhibitor | Non-Inhibitor | Non-Inhibitor | Inhibitor | Inhibitor |
| ROC transporter | Non-Inhibitor | Non-Inhibitor | Non-Inhibitor | Non-Inhibitor | Non-Inhibitor |

Distribution and metabolism

| CyP450 substrate | Non-Substrate | Non-Substrate | Non-Substrate | Non-Substrate | Non-Substrate |
|------------------|---------------|---------------|---------------|---------------|---------------|
| CyP450 2C9       | Non-Substrate | Non-Substrate | Non-Substrate | Non-Substrate | Non-Substrate |
| CyP450 2D6       | Non-Substrate | Non-Substrate | Non-Substrate | Non-Substrate | Non-Substrate |
| CyP450 3A4       | Substrate     | Substrate     | Substrate     | Substrate     | Non-Substrate |

| CyP450 inhibitor | Non-Inhibitor | Non-Inhibitor | Inhibitor | Inhibitor | Inhibitor |
|------------------|---------------|---------------|-----------|-----------|-----------|
| CyP450 1A2       | Non-Inhibitor | Non-Inhibitor | Inhibitor | Inhibitor | Inhibitor |
| CyP450 2C9       | Non-Inhibitor | Non-Inhibitor | Inhibitor | Inhibitor | Inhibitor |
CYP450 2C19  Non-Inhibitor  Non-Inhibitor  Inhibitor  Inhibitor  Inhibitor
CYP450 2D6  Non-Inhibitor  Non-Inhibitor  Inhibitor  Non-Inhibitor  Non-Inhibitor
CYP450 3A4  Non-Inhibitor  Non-Inhibitor  Non-Inhibitor  Non-Inhibitor  Non-Inhibitor
CYP1P  Low  Low  High  High  High

Excretion and toxicity
HERG inhibition  Inhibitor  Inhibitor  Non-Inhibitor  Non-Inhibitor  Non-Inhibitor
AMES toxicity  -  -  -  -  -
Carcinogen  -  -  -  -  -
Fish toxicity  High  High  High  High  High
Tt toxicity  High  High  High  High  High
H.l toxicity  High  High  High  High  High
Biodegradation  -  -  -  -  -

ADMET Predicted profile regression
Aqueous solubility  -3.6152  -3.9593  -3.2459  -3.4480  -3.1977
Caco2 permeability  1.1546  1.1143  1.1398  1.2832  1.1033

Toxicity
RAT, LDso mil/kg  1.8670  2.1861  2.4104  2.9080  2.6519
FT, pLC50 mg/L  1.7621  0.6695  0.2556  -0.3936  0.7986
TPT, PIGL50 µg/L  0.9295  1.1873  0.8237  0.5860  0.8149

Table 5: Biological activity spectrum of compounds (Pa – Active; Pi – Inactive)

| S. No | Name of the compounds | Pa  | Pi  | Activity          |
|-------|-----------------------|-----|-----|-------------------|
| 1     | Mucronulatol          | 0.676 | 0.008 | Antineoplastic    |
| 2     | Indigocarpan          | 0.670 | 0.014 | Antineoplastic    |
| 3     | Indigocarpan diacetate| 0.675 | 0.050 | Antineoplastic    |
| 4     | Erythroxydiol X       | 0.373 | 0.121 | Antineoplastic    |
| 5     | Erythroxydiol Y       | 0.342 | 0.047 | Antineoplastic    |

Table 6: Osiris calculation of compounds

| Name of the compound       | Predicted Toxicity Risks | Molecular Properties Calculations |
|----------------------------|--------------------------|----------------------------------|
|                            | Mut | Tumo | Irri | Rep | CLP | S   | MW  | DL  | D-S |
| Mucronulatol               | ●   | ●    | ●    | ●   | 3.29 | -2.93 | 302 | -0.62 | 0.45 |
| Erythroxydiol X            | ●   | ●    | ●    | ●   | 3.12 | -4.07 | 292 | -2.43 | 0.42 |
| Erythroxydiol Y            | ●   | ●    | ●    | ●   | 3.71 | -4.16 | 306 | -6.76 | 0.36 |
| Indigocarpan               | ●   | ●    | ●    | ●   | 2.91 | -2.75 | 316 | 0.84  | 0.73 |
| Indigocarpan diacetate     | ●   | ●    | ●    | ●   | 3.88 | -4.31 | 400 | -0.77 | 0.43 |
| Sorafenib (Positive control)| ●   | ●    | ●    | ●   | 4.27 | 6.69  | 464 | -4.2  | 0.2  |

MUT: mutagenic, TUMO: tumorigenic, IRRI: irritant, REP: reproductive effective, MW: Molecular weight, CLP: cLogP, S: solubility, DL: drug-likeness, D-S: drug-score. ● = Drug-conform behavior; ● = high risks of undesired effects, ○ = Moderate risk of undesirable effects.

Table 7: Binding energy and specific interaction of VEGFR2 with compounds

| No | Name of the compounds | Binding energy constant (µM) | Hydrogen bonding interactions | π - interactions |
|----|-----------------------|-----------------------------|-------------------------------|-----------------|
|    |                       | (kcal/mol)                  | No. of H bonds | Amino acid residues | Distance (Å) | Donor atom | Acceptor atom | Type | Amino acid residue | Distance (Å) |
| 1  | Indigocarpan          | -7.04 6.88                  | 2 | CYS 919 | 1.85 | H18 | O | π - σ | LEU 840 | 2.5 |
|    |                       |                             | | LYS 920 | 2.4 | H18 | O |    |        |      |
| S. No | Name of the compounds | Binding energy (kcal/mol) | Inhibitory constant (μM) | No. of H bonds | Amino acid residues | Distance (Å) | Donor atom | Acceptor atom | Type | Amino acid residues | Distance (Å) |
|-------|------------------------|--------------------------|-------------------------|----------------|------------------|-------------|------------|--------------|------|------------------|-------------|
| 1     | Indigocarpan           | -4.82                    | 293.55                  | 2              | THR 88           | 1.89        | HN         | O19          | -    | GLU 144          | 2.5         |
| 2     | Erythroxydiol X        | -4.11                    | 974.93                  | 1              | PHE 138          | 2.48        | HN         | O25          | π - π | PHE 138          | 4.750       |
| 3     | Erythroxydiol Y        | -4.7                     | 361.82                  | 2              | THR 143          | 1.91        | HG1        | O25          | -    | -                | -           |
| 4     | Mucronulatol           | -4.7                     | 356.51                  | 0              | -                | -           | -          | O            | π - π | PHE 138          | 3.94        |
| 5     | Indigocarpan diacetate | -4.58                    | 436.55                  | 1              | SER 296          | 2.01        | H37        | O            | π - π | PHE 138          | 4.29        |
| 6     | Sorafenib (+ve control)| -4.3                     | 709.45                  | 2              | ASP 106          | 2.47        | HN         | O6           | π - π | PHE 138          | 4.47        |

Table 8: Binding energy and specific interaction of PDGFRβ with compounds